For the short term, Alnylam is delivering two Plenary oral presentations and one poster on April 30:
Patisiran; International Symposium on Amyloidosis (ISA), April 27 - May 1. One Plenary paper further analyzes Phase 2 data of Patisiran.
Pending acceptance, more papers will be presented in the following meetings.
ALN-PCSsc; Arteriosclerosis, Thrombosis, and Vascular Biology, May 1 - 3
ALN-AAT; Digestive Disease Week, May 4 - 6
ALN-AT3; World Federation on Hemophilia, May 11 - 14
ALNY 5X15; TIDES, May 12 - 15
ALN-CC5; International Conference on Complement Therapeutics, June 6 - 11
For the time frame of October – December, look up my post of March 29: [[ When the data from ALN-AT3 for hemophilia A and B, -TTR02 for FAP, and -TTRsc for FAC come out, the share price could triple from here.]]